Equity
Pfizer·Balance Sheet Statement·9 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities and stockholders' equity | $216.2B | $219.5B | $213.4B | $208.0B | $206.1B | $208.7B | $208.2B | $207.6B |
| Retained earnings | $116.6B | $121.1B | $116.7B | $119.6B | $117.6B | $121.2B | $114.6B | $117.2B |
| Treasury stock | $114.8B | $114.8B | $114.8B | $115.0B | $115.0B | $115.0B | $115.0B | $115.2B |
| Additional paid-in capital | $93.2B | $93.5B | $93.6B | $93.9B | $94.1B | $94.2B | $94.5B | $94.8B |
| Total stockholders' equity | $87.7B | $92.3B | $88.2B | $90.3B | $88.7B | $92.8B | $86.5B | $90.1B |
| Accumulated other comprehensive income (loss) | -$7.8B | -$8.0B | -$7.8B | -$8.6B | -$8.4B | -$8.1B | -$8.1B | -$7.2B |
| Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | $480.0M | $480.0M | $480.0M | $481.0M | $481.0M | $481.0M | $481.0M | $482.0M |
| Debt Securities (Trading and AFS) - Accumulated Gross Unrealized Gain | $6.0M | $55.0M | $8.0M | $39.0M | $87.0M | $2.0M | $3.0M | $29.0M |
| Debt Securities (Trading and AFS) - Accumulated Gross Unrealized Loss | $7.0M | $3.0M | $129.0M | $36.0M | $1.0M | $24.0M | $35.0M | $2.0M |